Polaryx Therapeutics (PLYX) investor relations material

Executive summary

• Clinical-stage biotech focused on therapies for rare pediatric lysosomal storage disorders, advancing a pipeline led by PLX-200, with a Phase 2 basket trial (SOTERIA) expected to start in H2 2026.

• No products approved or revenue from product sales; operations funded primarily through equity issuances totaling $31.5 million to date.

• Net losses continue as R&D and public company expenses rise; cash runway expected through Q1 2027.

Financial highlights

• Net loss for Q2 2026 was $1.4 million, compared to $1.0 million in Q2 2025; net loss for the six months ended June 30, 2026 was $3.9 million, down from $6.1 million in the prior year period.

• Operating expenses for Q2 2026 were $1.4 million, up $496 thousand year-over-year, driven by higher R&D and G&A costs.

• Cash and cash equivalents as of June 30, 2026 were $11.5 million, up from $5.1 million at year-end 2025, due to a $10 million equity raise in May 2026.

• No outstanding debt as of June 30, 2026.

Outlook and guidance

• Cash runway expected to fund operations through Q1 2027; additional capital will be needed beyond that period.

• Anticipates increased R&D and G&A expenses as clinical programs advance and public company costs rise.

• SOTERIA Phase 2 trial for PLX-200 to initiate in H2 2026, with expanded enrollment to 24 participants.